ImmunityBio (IBRX) Cost of Revenue (2025 - 2026)
ImmunityBio (IBRX) posted quarterly Cost of Revenue of $238000.0 for Q1 2026, up 310.34% year-over-year from $58000.0 in Q1 2025, and down 37.7% quarter-over-quarter from $382000.0 in Q4 2025.
Powered by 
Analysis
ImmunityBio (IBRX) Cost of Revenue (2025 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported Cost of Revenue for 2 consecutive years, with $238000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cost of Revenue rose 310.34% year-over-year to $238000.0; the TTM figure through Mar 2026 stood at $933000.0 (up 1508.62% YoY), while the FY2025 annual figure was $753000.0, changed N/A from the prior year.
- Cost of Revenue retreated to $238000.0 in Q1 2026 per IBRX's latest filing, from $382000.0 in the prior quarter.
- Across five years, Cost of Revenue topped out at $382000.0 in Q4 2025 and bottomed at $58000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 145.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 93.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 174.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 298.26 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 67.21 Mn |
| 10 | ImmunityBio | 8.48 Bn | 8.12 Bn | 50.94 Mn | 298,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 298,000.00 |
| Mar 31, 2026 | 238,000.00 |
| Dec 31, 2025 | 382,000.00 |
| Sep 30, 2025 | 177,000.00 |
| Jun 30, 2025 | 136,000.00 |
| Mar 31, 2025 | 58,000.00 |